Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • 4D Pharma, University College Cork deal

    4D Pharma plc (LSE:DDDD), Manchester, U.K. University College Cork, Cork, Ireland Business: Neurology 4D partnered with the universitys APC Microbiome Institute to research live biotherapeutics to treat autism and …

    Published on 9/28/2015
  • AcelRx, Gruenenthal, PDL BioPharma deal

    AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX), Redwood City, Calif. Gruenenthal Group, Aachen, Germany PDL BioPharma Inc. (NASDAQ:PDLI), Incline Village, Nev. Business: Neurology AcelRx sold to PDL a portion of the …

    Published on 9/28/2015
  • Addex, Pierre Fabre Group deal

    Addex Therapeutics Ltd. (SIX:ADXN), Geneva, Switzerland Pierre Fabre Group, Castres, France Business: Neurology Addex granted Pierre Fabre an option to license a metabotropic glutamate receptor subtype 3 (mGluR3; GRM3) …

    Published on 9/28/2015
  • Allergan, Ironwood deal

    Allergan plc (NYSE:AGN), Dublin, Ireland Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Business: Gastrointestinal Allergan granted Ironwood rights to co-promote Viberzi eluxadoline in the U.S. Ironwood …

    Published on 9/28/2015
  • AstraZeneca, Mitsubishi Tanabe Pharma deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Business: Cancer AstraZenecas MedImmune LLC unit granted Mitsubishis Tanabe Research Laboratories (TRL) …

    Published on 9/28/2015
  • Aveo Pharmaceuticals, Pharmstandard deal

    Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass. Pharmstandard OJSC (RTS:PHST;LSE:PHST), Dolgoprudny, Russia Business: Cancer Aveo granted Pharmstandard exclusive rights to develop and commercialize tivozanib …

    Published on 9/28/2015
  • Bill & Melinda Gates Foundation, CureVac deal

    Bill & Melinda Gates Foundation, Seattle, Wash. CureVac GmbH, Tuebingen, Germany Business: Infectious CureVac began its third product development program with the Bill & Melinda Gates foundation. The preclinical program…

    Published on 9/28/2015
  • Biocept, University of California Irvine deal

    Biocept Inc. (NASDAQ:BIOC), San Diego, Calif. University of California Irvine, Irvine, Calif. Business: Diagnostic, Cancer Biocept partnered with the university to evaluate the biotechs liquid biopsy biomarker assays in…

    Published on 9/28/2015
  • Calibrium, Novo Nordisk deal

    Calibrium LLC, Indianapolis, Ind. Novo Nordisk A/S (CSE:NVO;NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Novo will acquire biopharma Calibrium for an undisclosed sum. The company develops therapeutics to …

    Published on 9/28/2015
  • Celyad, Medisun International deal

    Celyad S.A. (Euronext:CYAD;NASDAQ:CYAD), Mont-Saint-Guibert, Belgium Medisun International Ltd., Hong Kong, China Business: Cardiovascular Celyad granted Medisun rights to commercialize C-Cure in Taiwan and China, …

    Published on 9/28/2015
  • Clovis, Genentech, Roche deal

    Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cancer Clovis and Roches Genentech unit partnered to evaluate …

    Published on 9/28/2015
  • Codexis deal

    Codexis Inc. (NASDAQ:CDXS), Redwood City, Calif. Business: Pharmaceuticals Codexis will use its CodeEvolver platform to develop an enzyme for use in an undisclosed companys preclinical therapeutic development program. …

    Published on 9/28/2015
  • Cytovance Biologics, Shenzhen Hepalink Pharmaceutical deal

    Cytovance Biologics LLC, Oklahoma City, Okla. Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399), Shenzhen, China Business: Biomanufacturing Shenzhens Hepalink USA Inc. subsidiary will acquire contract biologics …

    Published on 9/28/2015
  • Daiichi Sankyo, AstraZeneca deal

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Infectious AstraZenecas MedImmune LLC unit granted Daiichi Sankyo exclusive rights to develop and …

    Published on 9/28/2015
  • Eisai, Halozyme deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Business: Cancer The companies partnered jointly fund a Phase Ib/II trial of Eisais breast cancer drug Halaven …

    Published on 9/28/2015
  • Evotec, CHDI Foundation deal

    Evotec AG (Xetra:EVT), Hamburg, Germany CHDI Foundation Inc., New York, N.Y. Business: Neurology Evotec and CHDI extended through August 2018 a 2006 deal under which Evotec is providing the nonprofit with medicinal …

    Published on 9/28/2015
  • Fetolumina, Cytolumina, Sorrento deal

    Fetolumina Technologies Corp., Walnut, Calif. Cytolumina Technology Corp. Inc., Walnut, Calif. Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Business: Cancer Sorrento received exclusive rights from …

    Published on 9/28/2015
  • Hemispherx, Emerge Health deal

    Hemispherx Biopharma Inc. (NYSE-M:HEB), Philadelphia, Pa. Emerge Health Pty. Ltd., Canterbury, Australia Business: Infectious Hemispherx granted Emerge exclusive rights to develop and commercialize Alferon N Injection …

    Published on 9/28/2015
  • Indiana University, University of Alabama at Birmingham, La Jolla Pharmaceutical deal

    Indiana University, Indianapolis, Ind. University of Alabama at Birmingham, Birmingham, Ala. La Jolla Pharmaceutical Co. (NASDAQ:LJPC), San Diego, Calif. Business: Infectious La Jolla exercised an exclusive option to …

    Published on 9/28/2015
  • Intrexon, Synthetic Biologics deal

    Intrexon Corp. (NYSE:XON), Germantown, Md. Synthetic Biologics Inc. (NYSE-M:SYN), Rockville, Md. Business: Drug delivery, Endocrine/Metabolic Intrexon granted Synthetic Biologics exclusive, worldwide rights to develop …

    Published on 9/28/2015
  • MB2, Novo Nordisk deal

    MB2 LLC, Carmel, Ind. Novo Nordisk A/S (CSE:NVO;NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Novo will acquire biopharma MB2 for an undisclosed sum. The company develops therapeutics to treat diabetes and…

    Published on 9/28/2015
  • Merck KGaA, Relief Therapeutics deal

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Relief Therapeutics, Geneva, Switzerland Business: Neurology Merck granted Relief exclusive, worldwide rights to develop and commercialize atexakin alfa, which the Relief plans…

    Published on 9/28/2015
  • Nanotherapeutics, Takeda deal

    Nanotherapeutics Inc., Alachua, Fla. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Infectious The partners will expand Takedas commercialization and technology access rights related to …

    Published on 9/28/2015
  • Nuclea, IRCM deal

    Nuclea Biotechnologies Inc., Pittsfield, Mass. Institut de Recherches Cliniques de Montreal (IRCM), Montreal, Quebec Business: Diagnostic, Endocrine/Metabolic Nuclea and the IRCM plan to develop quantitative mass …

    Published on 9/28/2015
  • Phoundry Pharmaceuticals, Intarcia deal

    Phoundry Pharmaceuticals Inc., Research Triangle Park, N.C. Intarcia Therapeutics Inc., Boston, Mass. Business: Endocrine/Metabolic Intarcia acquired Phoundry for an undisclosed sum. The deal gives Intarcia a portfolio …

    Published on 9/28/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993